Novocure shares climb after higher first-quarter revenue and raised outlook
Updated
Updated · MarketWatch · Apr 30
Novocure shares climb after higher first-quarter revenue and raised outlook
8 articles · Updated · MarketWatch · Apr 30
The stock jumped 27% to $15.20 after revenue rose 12% to $174.1 million, above the $167.8 million analysts expected.
Novocure now forecasts full-year revenue of $690 million to $710 million, compared with a FactSet consensus of $698.9 million, helped by active patient growth in European markets.
The oncology company reported a wider net loss of $71.1 million, or 62 cents a share, from $24.3 million, while the shares remain up 17% so far this year.
With Novocure’s share surge but rising losses, can TTFields therapy truly disrupt cancer care or will financial pressures slow its progress?
After FDA approval of Optune Pax, how soon could this device become the new standard for pancreatic cancer, and what barriers remain to widespread adoption?